StockNews.AI
BCAB
StockNews.AI
168 days

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

1. The AXL Inhibitors report highlights 20+ pipeline drugs under development. 2. Key players include Exelixis, BioAtla, and Sumitomo Dainippon Pharma. 3. The report emphasizes emerging drugs targeting solid tumors, particularly in cancer treatment. 4. Key collaborators are involved in the global development of AXL Inhibitors. 5. The report identifies various drug phases, focusing on substantial clinical stages.

8m saved
Insight
Article

FAQ

Why Bullish?

The focus on AXL inhibitors indicates potential growth in oncology treatments. Historical movements suggest stock price increases in response to positive oncology pipeline news.

How important is it?

The emphasis on emerging AXL inhibitors ties into BCAB's focus areas, indicating a relevant growth potential.

Why Long Term?

Long-term developments in AXL inhibitors could reshape treatment paradigms, benefiting BCAB's strategic positioning as therapies advance.

Related Companies

EXELABTRGENGILD
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "AXL Inhibitors - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 16+ companies and 20+ pipeline drugs in AXL Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Report HighlightsCompanies and academics are working to assess challenges and seek opportunities that could influence AXL Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve AXL Inhibitors.AXL Inhibitors Emerging Drugs ChaptersThis segment of the AXL Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Emerging Drugs Cabozantinib: Exelixis/Ipsen Exelixis' flagship compound, cabozantinib, is a targeted agent that inhibits the activity of receptor tyrosine kinases, including MET, AXL, VEGF receptors, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and resistance to multiple therapies, including immune checkpoint inhibitors (ICIs). Exelixis and its partners are collaborating on the global development plan for cabozantinib, and Ipsen and Takeda are responsible for the cabozantinib development work specific to their respective regions.Cabozantinib is being developed by Exelixis/Ipsen and is currently in Phase III for Non-Small Cell Lung Cancer and Prostate Cancer. BA 3011: BioAtla BA3011 (CAB-AXL-ADC) is a CAB antibody drug conjugate that targets the receptor tyrosine kinase AXL. AXL is an important target as they are expressed in many solid tumors with higher frequency of expression observed in tumors previously treated with anti-PD-1 therapy. This, coupled with the therapeutic index advantages provided by BioAtla's proprietary CAB technology, lends strong rationale for investigating BA3011 and BA3021 in combination with Opdivo. The drug is in the Phase II stage of development for the treatment of ovarian cancer and Non-Small-Cell Lung Cancer. TP-0903: Sumitomo Dainippon Pharma Oncology TP-0903 is an AXL receptor tyrosine kinase inhibitor, which is known to be involved in acquiring resistance to conventional agents and developing metastatic capacity in cancer cells. TP-0903 may have anti-cancer activities on various cancer types through blocking transition from epithelial to mesenchymal phenotype by inhibiting AXL. TP-0903 may have anti-cancer activities on various cancer types through blocking transition from epithelial to mesenchymal phenotype by inhibiting AXL. TP-0903 has been shown to inhibit AXL signaling and reverse the mesenchymal to epithelial phenotype in pre-clinical studies. It is currently in Phase I/II for Advanced Solid Tumors.AXL Inhibitors: Therapeutic AssessmentThis segment of the report provides insights about the different AXL Inhibitors drugs segregated based on following parameters that define the scope of the report.Major PlayersThere are approx. 16+ key companies which are developing the therapies for AXL Inhibitors. The companies which have their AXL Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Exelixis. ExelixisBioAtlaSumitomo Dainippon Pharma OncologyMirati TherapeuticsAraviveOno PharmaceuticalBerGenBioHEC PharmExelixisBetta Pharmaceuticals Phases The report covers around 20+ products under different phases of clinical development, like: Late stage products (Phase III)Mid-stage products (Phase II)Early-stage product (Phase I) along with the details ofPre-clinical and Discovery stage candidatesDiscontinued & Inactive candidates Route of AdministrationProducts have been categorized under various ROAs, such as: Intra-articularIntraocularIntrathecalIntravenousOralParenteralSubcutaneousTopicalTransdermal Molecule Type Products have been categorized under various Molecule types, such as: OligonucleotidePeptideSmall molecule Product TypeDrugs have been categorized under various product types like Mono, Combination and Mono/Combination.Pipeline ActivitiesThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses AXL Inhibitors therapeutic drugs key players involved in developing key drugs.Development ActivitiesThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL Inhibitors drugs. Key Questions Answered How many companies are developing AXL Inhibitors drugs?How many AXL Inhibitors drugs are developed by each company?How many emerging drugs are in mid-stage, and late-stage of development for the treatment of AXL Inhibitors?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the AXL Inhibitors therapeutics?What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?What are the clinical studies going on for AXL Inhibitors and their status?What are the key designations that have been granted to the emerging drugs? Key Products BatiraxceptCabozantinibSitravatinibONO-7475BemcentinibBA3011CT053TP-0903XL092BPI-9016M For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lwrgof About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News